Skip to main content
Top

08-07-2024 | Prostate Cancer | Review

Targeted biopsy of the prostate

Authors: David W. Schroeder, Bryan R. Foster, Daniel J. Young, Fergus V. Coakley

Published in: Abdominal Radiology

Login to get access

Abstract

Diagnostic multiparametric MRI of the prostate has steadily evolved over the last three decades and can now reliably depict the dominant tumor in most men with prostate cancer. In response, several methods of targeted biopsy to direct tissue sampling of suspected tumor foci seen at multiparametric MRI have been developed and successfully tested in recent years, including software-assisted MRI-ultrasound (US) fusion biopsy and direct MRI-guided in-bore biopsy. These advances are leading to a sea change in the approach to prostate cancer diagnosis, with the traditional approach of blind systematic biopsy increasingly being replaced by MRI directed targeted biopsy. This review aims to describe the current status of targeted biopsy, with an emphasis on the relative accuracy of different techniques. The results of several critical large multicenter trials are presented, while unanswered questions that require more research are highlighted.
Literature
1.
go back to reference American Cancer Society. Cancer Facts and Fig. 2024. Atlanta: American Cancer Society; 2024: 4. American Cancer Society. Cancer Facts and Fig. 2024. Atlanta: American Cancer Society; 2024: 4.
3.
go back to reference Seikkula HA, Kaipia AJ, Rantanen ME, Pitkäniemi JM, Malila NK, Boström PJ. Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA. Acta Oncologica 2017; 56: 971–977.PubMedCrossRef Seikkula HA, Kaipia AJ, Rantanen ME, Pitkäniemi JM, Malila NK, Boström PJ. Stage-specific mortality and survival trends of prostate cancer patients in Finland before and after introduction of PSA. Acta Oncologica 2017; 56: 971–977.PubMedCrossRef
4.
go back to reference Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142, 71–75.PubMedCrossRef Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142, 71–75.PubMedCrossRef
5.
go back to reference Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M, and PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2019; 389: 815–822.CrossRef Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP, Oldroyd R, Parker C, Emberton M, and PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2019; 389: 815–822.CrossRef
6.
go back to reference Bott SR, Young MP, Kellett MJ, Parkinson MC; Contributors to the UCL Hospitals’ Trust Radical Prostatectomy Database. Anterior prostate cancer: is it more difficult to diagnose? BJU Int 2002; 89: 886–9.PubMedCrossRef Bott SR, Young MP, Kellett MJ, Parkinson MC; Contributors to the UCL Hospitals’ Trust Radical Prostatectomy Database. Anterior prostate cancer: is it more difficult to diagnose? BJU Int 2002; 89: 886–9.PubMedCrossRef
7.
go back to reference Djavan B, Milani S, Remzi M. Prostate biopsy: who, how and when. An update. Can J Urol. 2005;12 Suppl 1:44 – 8; discussion 99–100. PMID: 15780165. Djavan B, Milani S, Remzi M. Prostate biopsy: who, how and when. An update. Can J Urol. 2005;12 Suppl 1:44 – 8; discussion 99–100. PMID: 15780165.
8.
go back to reference Gallina A, Suardi N, Montorsi F, Capitanio U, Jeldres C, Saad F, Graefen M, Shariat SF, Widmer H, Arjane P, Péloquin F, Perrotte P, Karakiewicz PI. Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men. Int J Cancer 2008; 123: 647–52.PubMedCrossRef Gallina A, Suardi N, Montorsi F, Capitanio U, Jeldres C, Saad F, Graefen M, Shariat SF, Widmer H, Arjane P, Péloquin F, Perrotte P, Karakiewicz PI. Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men. Int J Cancer 2008; 123: 647–52.PubMedCrossRef
9.
go back to reference Wei TC, Lin TP, Chang YH, Chen TJ, Lin AT, Chen KK. Transrectal ultrasound-guided prostate biopsy in Taiwan: A nationwide database study. J Chin Med Assoc 2015; 78: 662–5.PubMedCrossRef Wei TC, Lin TP, Chang YH, Chen TJ, Lin AT, Chen KK. Transrectal ultrasound-guided prostate biopsy in Taiwan: A nationwide database study. J Chin Med Assoc 2015; 78: 662–5.PubMedCrossRef
10.
go back to reference Hiraki T, Mimura H, Gobara H, et al. CT fluoroscopy-guided biopsy of 1,000 pulmonary lesions performed with 20-gauge coaxial cutting needles: diagnostic yield and risk factors for diagnostic failure. Chest 2009; 136: 1612–7PubMedCrossRef Hiraki T, Mimura H, Gobara H, et al. CT fluoroscopy-guided biopsy of 1,000 pulmonary lesions performed with 20-gauge coaxial cutting needles: diagnostic yield and risk factors for diagnostic failure. Chest 2009; 136: 1612–7PubMedCrossRef
11.
go back to reference Jackman RJ, Nowels KW, Rodriguez-Soto J, Marzoni FA Jr, Finkelstein SI, Shepard MJ. Stereotactic, automated, large-core needle biopsy of nonpalpable breast lesions: false-negative and histologic underestimation rates after long-term follow-up. Radiology 1999; 210: 799–805.PubMedCrossRef Jackman RJ, Nowels KW, Rodriguez-Soto J, Marzoni FA Jr, Finkelstein SI, Shepard MJ. Stereotactic, automated, large-core needle biopsy of nonpalpable breast lesions: false-negative and histologic underestimation rates after long-term follow-up. Radiology 1999; 210: 799–805.PubMedCrossRef
12.
go back to reference Rex DK, Cutler CS, Lemmel GT, Rahmani EY, Clark DW, Helper DJ, Lehman GA, Mark DG. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology. 1997; 112: 24–8.PubMedCrossRef Rex DK, Cutler CS, Lemmel GT, Rahmani EY, Clark DW, Helper DJ, Lehman GA, Mark DG. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology. 1997; 112: 24–8.PubMedCrossRef
14.
go back to reference Hong A, Hemmingway S, Wetherell D, Dias B, Zargar H. Outpatient transperineal prostate biopsy under local anaesthesia is safe, well tolerated and feasible. ANZ Journal of Surgery, 2022; 92: 1480–1485.PubMedPubMedCentralCrossRef Hong A, Hemmingway S, Wetherell D, Dias B, Zargar H. Outpatient transperineal prostate biopsy under local anaesthesia is safe, well tolerated and feasible. ANZ Journal of Surgery, 2022; 92: 1480–1485.PubMedPubMedCentralCrossRef
15.
go back to reference Hogan D, Kanagarajah A, Yao HH, Wetherell D, Dias B, Dundee P, Chu K, Zargar H, O’Connell HE. Local versus general anesthesia transperineal prostate biopsy: Tolerability, cancer detection, and complications. BJUI Compass. 2021; 2: 428–435.PubMedPubMedCentralCrossRef Hogan D, Kanagarajah A, Yao HH, Wetherell D, Dias B, Dundee P, Chu K, Zargar H, O’Connell HE. Local versus general anesthesia transperineal prostate biopsy: Tolerability, cancer detection, and complications. BJUI Compass. 2021; 2: 428–435.PubMedPubMedCentralCrossRef
16.
go back to reference Günzel K, Magheli A, Baco E, Cash H, Heinrich S, Neubert H, Schlegel J, Schostak M, Henkel T, Asbach P, Hinz S. Infection rate and complications after 621 transperineal MRI-TRUS fusion biopsies in local anesthesia without standard antibiotic prophylaxis. World J Urol 2021; 39: 3861–3866.PubMedCrossRef Günzel K, Magheli A, Baco E, Cash H, Heinrich S, Neubert H, Schlegel J, Schostak M, Henkel T, Asbach P, Hinz S. Infection rate and complications after 621 transperineal MRI-TRUS fusion biopsies in local anesthesia without standard antibiotic prophylaxis. World J Urol 2021; 39: 3861–3866.PubMedCrossRef
17.
18.
go back to reference Carter HB, Hamper UM, Sheth S, Sanders RC, Epstein JI, Walsh PC. Evaluation of transrectal ultrasound in the early detection of prostate cancer. J Urol 1989; 142: 1008–10.PubMedCrossRef Carter HB, Hamper UM, Sheth S, Sanders RC, Epstein JI, Walsh PC. Evaluation of transrectal ultrasound in the early detection of prostate cancer. J Urol 1989; 142: 1008–10.PubMedCrossRef
19.
go back to reference Das CJ, Razik A, Netaji A, Verma S. Prostate MRI-TRUS fusion biopsy: a review of the state of the art procedure. Abdom Radiol 2020; 45: 2176–2183.CrossRef Das CJ, Razik A, Netaji A, Verma S. Prostate MRI-TRUS fusion biopsy: a review of the state of the art procedure. Abdom Radiol 2020; 45: 2176–2183.CrossRef
20.
go back to reference Puech P, Ouzzane A, Gaillard V, Betrouni N, Renard B, Villers A, Lemaitre L. Multiparametric MRI-targeted TRUS prostate biopsies using visual registration. Biomed Res Int. 2014: 819360. Puech P, Ouzzane A, Gaillard V, Betrouni N, Renard B, Villers A, Lemaitre L. Multiparametric MRI-targeted TRUS prostate biopsies using visual registration. Biomed Res Int. 2014: 819360.
21.
go back to reference Schiavina R, Vagnoni V, D’Agostino D, Borghesi M, Salvaggio A, Giampaoli M, Pultrone CV, Saraceni G, Gaudiano C, Vigo M, Bianchi L, Dababneh H, La Manna G, Chessa F, Romagnoli D, Martorana G, Brunocilla E, Porreca A. “In-bore” MRI-guided Prostate Biopsy Using an Endorectal Nonmagnetic Device: A Prospective Study of 70 Consecutive Patients. Clin Genitourin Cancer 2017; 15: 417–427.PubMedCrossRef Schiavina R, Vagnoni V, D’Agostino D, Borghesi M, Salvaggio A, Giampaoli M, Pultrone CV, Saraceni G, Gaudiano C, Vigo M, Bianchi L, Dababneh H, La Manna G, Chessa F, Romagnoli D, Martorana G, Brunocilla E, Porreca A. “In-bore” MRI-guided Prostate Biopsy Using an Endorectal Nonmagnetic Device: A Prospective Study of 70 Consecutive Patients. Clin Genitourin Cancer 2017; 15: 417–427.PubMedCrossRef
22.
go back to reference Patel N, Coakley FV, Foster BR. Performance of transgluteal CT-guided biopsy of prostate lesions in men without rectal access: A retrospective study. Clin Imaging. 2021; 79: 225–229.PubMedCrossRef Patel N, Coakley FV, Foster BR. Performance of transgluteal CT-guided biopsy of prostate lesions in men without rectal access: A retrospective study. Clin Imaging. 2021; 79: 225–229.PubMedCrossRef
23.
go back to reference Maccagnano C, Gallina A, Roscigno M, Raber M, Capitanio U, Saccà A, Pellucchi F, Suardi N, Abdollah F, Montorsi F, Rigatti P, Scattoni V. Prostate saturation biopsy following a first negative biopsy: state of the art. Urol Int 2012; 89: 126–35.PubMedCrossRef Maccagnano C, Gallina A, Roscigno M, Raber M, Capitanio U, Saccà A, Pellucchi F, Suardi N, Abdollah F, Montorsi F, Rigatti P, Scattoni V. Prostate saturation biopsy following a first negative biopsy: state of the art. Urol Int 2012; 89: 126–35.PubMedCrossRef
24.
go back to reference Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166: 86–91.PubMedCrossRef Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166: 86–91.PubMedCrossRef
25.
go back to reference Kasivisvanathan V, Rannikko AS, Borghi M, et al; PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 2018 10;378: 1767–1777.PubMedCrossRef Kasivisvanathan V, Rannikko AS, Borghi M, et al; PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med 2018 10;378: 1767–1777.PubMedCrossRef
26.
go back to reference Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier F, Decaussin-Petrucci M, Dubreuil-Chambardel M, Magaud L, Remontet L, Ruffion A, Colombel M, Crouzet S, Schott AM, Lemaitre L, Rabilloud M, Grenier N; MRI-FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 2019; 20: 100–109.PubMedCrossRef Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier F, Decaussin-Petrucci M, Dubreuil-Chambardel M, Magaud L, Remontet L, Ruffion A, Colombel M, Crouzet S, Schott AM, Lemaitre L, Rabilloud M, Grenier N; MRI-FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol 2019; 20: 100–109.PubMedCrossRef
27.
go back to reference Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, Bloom J, Gurram S, Siddiqui M, Pinsky P, Parnes H, Linehan WM, Merino M, Choyke PL, Shih JH, Turkbey B, Wood BJ, Pinto PA. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med 2020; 382: 917–928.PubMedPubMedCentralCrossRef Ahdoot M, Wilbur AR, Reese SE, Lebastchi AH, Mehralivand S, Gomella PT, Bloom J, Gurram S, Siddiqui M, Pinsky P, Parnes H, Linehan WM, Merino M, Choyke PL, Shih JH, Turkbey B, Wood BJ, Pinto PA. MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis. N Engl J Med 2020; 382: 917–928.PubMedPubMedCentralCrossRef
28.
go back to reference Wysock JS, Rosenkrantz AB, Huang WC, Stifelman MD, Lepor H, Deng FM, Melamed J, Taneja SS. A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial. Eur Urol 2014; 66: 343–51.PubMedCrossRef Wysock JS, Rosenkrantz AB, Huang WC, Stifelman MD, Lepor H, Deng FM, Melamed J, Taneja SS. A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial. Eur Urol 2014; 66: 343–51.PubMedCrossRef
29.
go back to reference Felker ER, Lee-Felker SA, Feller J, Margolis DJ, Lu DS, Princenthal R, May S, Cohen M, Huang J, Yoshida J, Greenwood B, Kim HJ, Raman SS. In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer. Abdom Radiol 2016; 41: 954–62.CrossRef Felker ER, Lee-Felker SA, Feller J, Margolis DJ, Lu DS, Princenthal R, May S, Cohen M, Huang J, Yoshida J, Greenwood B, Kim HJ, Raman SS. In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer. Abdom Radiol 2016; 41: 954–62.CrossRef
30.
go back to reference Quentin M, Blondin D, Arsov C, Schimmöller L, Hiester A, Godehardt E, Albers P, Antoch,G, Rabenalt R. Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen. J Urol 2014: 192: 1374–1379.PubMedCrossRef Quentin M, Blondin D, Arsov C, Schimmöller L, Hiester A, Godehardt E, Albers P, Antoch,G, Rabenalt R. Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen. J Urol 2014: 192: 1374–1379.PubMedCrossRef
31.
go back to reference Kaufmann S, Kruck S, Kramer U, Gatidis S, Stenzl A, Roethke M, Scharpf M, Schilling D. Direct comparison of targeted MRI-guided biopsy with systematic transrectal ultrasound-guided biopsy in patients with previous negative prostate biopsies. Urol Int 2015;94: 319–25.PubMedCrossRef Kaufmann S, Kruck S, Kramer U, Gatidis S, Stenzl A, Roethke M, Scharpf M, Schilling D. Direct comparison of targeted MRI-guided biopsy with systematic transrectal ultrasound-guided biopsy in patients with previous negative prostate biopsies. Urol Int 2015;94: 319–25.PubMedCrossRef
32.
go back to reference D’Agostino D, Romagnoli D, Giampaoli M, Bianchi FM, Corsi P, Del Rosso A, Schiavina R, Brunocilla E, Artibani W, Porreca A. “In-Bore” MRI-Guided Prostate Biopsy for Prostate Cancer Diagnosis: Results from 140 Consecutive Patients. Curr Urol. 2020; 14: 22–31.PubMedPubMedCentralCrossRef D’Agostino D, Romagnoli D, Giampaoli M, Bianchi FM, Corsi P, Del Rosso A, Schiavina R, Brunocilla E, Artibani W, Porreca A. “In-Bore” MRI-Guided Prostate Biopsy for Prostate Cancer Diagnosis: Results from 140 Consecutive Patients. Curr Urol. 2020; 14: 22–31.PubMedPubMedCentralCrossRef
33.
go back to reference van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J, van den Hout H, van der Lelij H, van Oort I, Klaver S, Debruyne F, Sedelaar M, Hannink G, Rovers M, Hulsbergen-van de Kaa C, Barentsz JO. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. Eur Urol 2019; 75: 570–578.PubMedCrossRef van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J, van den Hout H, van der Lelij H, van Oort I, Klaver S, Debruyne F, Sedelaar M, Hannink G, Rovers M, Hulsbergen-van de Kaa C, Barentsz JO. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. Eur Urol 2019; 75: 570–578.PubMedCrossRef
34.
go back to reference Hale GR, Czarniecki M, Cheng A, et al. Comparison of elastic and rigid registration during Magnetic Resonance Imaging/ultrasound fusion-guided prostate biopsy: A multi-operator phantom study. J Urol 2018; 200: 1114–1121.PubMedPubMedCentralCrossRef Hale GR, Czarniecki M, Cheng A, et al. Comparison of elastic and rigid registration during Magnetic Resonance Imaging/ultrasound fusion-guided prostate biopsy: A multi-operator phantom study. J Urol 2018; 200: 1114–1121.PubMedPubMedCentralCrossRef
35.
go back to reference Venderink W, van der Leest M, van Luijtelaar A, van de Ven WJM, Fütterer JJ, Sedelaar JPM, Huisman HJ. Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer. World J Urol 2017; 35: 1849–1855.PubMedPubMedCentralCrossRef Venderink W, van der Leest M, van Luijtelaar A, van de Ven WJM, Fütterer JJ, Sedelaar JPM, Huisman HJ. Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer. World J Urol 2017; 35: 1849–1855.PubMedPubMedCentralCrossRef
36.
go back to reference Costa DN, Goldberg K, Leon AD, Lotan Y, Xi Y, Aziz M, Freifeld Y, Margulis V, Raj G, Roehrborn CG, Hornberger B, Desai N, Bagrodia A, Francis F, Pedrosa I, Cadeddu JA. Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate. Eur Urol Oncol 2019; 2: 397–404.PubMedCrossRef Costa DN, Goldberg K, Leon AD, Lotan Y, Xi Y, Aziz M, Freifeld Y, Margulis V, Raj G, Roehrborn CG, Hornberger B, Desai N, Bagrodia A, Francis F, Pedrosa I, Cadeddu JA. Magnetic Resonance Imaging-guided In-bore and Magnetic Resonance Imaging-transrectal Ultrasound Fusion Targeted Prostate Biopsies: An Adjusted Comparison of Clinically Significant Prostate Cancer Detection Rate. Eur Urol Oncol 2019; 2: 397–404.PubMedCrossRef
37.
go back to reference Prince M, Foster BR, Kaempf A, Liu JJ, Amling CL, Isharwal S, Chen Y, Coakley FV. In-Bore Versus Fusion MRI-Targeted Biopsy of PI-RADS Category 4 and 5 Lesions: A Retrospective Comparative Analysis Using Propensity Score Weighting. AJR Am J Roentgenol. 2021; 217: 1123–1130.PubMedCrossRef Prince M, Foster BR, Kaempf A, Liu JJ, Amling CL, Isharwal S, Chen Y, Coakley FV. In-Bore Versus Fusion MRI-Targeted Biopsy of PI-RADS Category 4 and 5 Lesions: A Retrospective Comparative Analysis Using Propensity Score Weighting. AJR Am J Roentgenol. 2021; 217: 1123–1130.PubMedCrossRef
38.
go back to reference Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, Bosch JLHR, Barentsz JO, Somford DM, van Melick HHE. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol 2019; 75: 582–590.PubMedCrossRef Wegelin O, Exterkate L, van der Leest M, Kummer JA, Vreuls W, de Bruin PC, Bosch JLHR, Barentsz JO, Somford DM, van Melick HHE. The FUTURE Trial: A Multicenter Randomised Controlled Trial on Target Biopsy Techniques Based on Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer in Patients with Prior Negative Biopsies. Eur Urol 2019; 75: 582–590.PubMedCrossRef
39.
go back to reference Wegelin O, van Melick HHE, Hooft L, Ruud Bosch JLH, Reitsma HB, Barentxz JO, et al. Comparing three different techniques for magnetic resonance imagingtargeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive regsitration. is there a preferred technique? Eur Urol. 2017; 71: 517–31.PubMedCrossRef Wegelin O, van Melick HHE, Hooft L, Ruud Bosch JLH, Reitsma HB, Barentxz JO, et al. Comparing three different techniques for magnetic resonance imagingtargeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive regsitration. is there a preferred technique? Eur Urol. 2017; 71: 517–31.PubMedCrossRef
40.
go back to reference Bass EJ, Pantovic A, Connor MJ, Loeb S, Rastinehad AR, Winkler M, Gabe R, Ahmed HU. Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2022; 25: 174–179.PubMedCrossRef Bass EJ, Pantovic A, Connor MJ, Loeb S, Rastinehad AR, Winkler M, Gabe R, Ahmed HU. Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2022; 25: 174–179.PubMedCrossRef
41.
go back to reference Borkowetz A, Hadaschik B, Platzek I, Toma M, Torsev G, Renner T, Herout R, Baunacke M, Laniado M, Baretton G, Radtke JP, Kesch C, Hohenfellner M, Froehner M, Schlemmer HP, Wirth M, Zastrow S. Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naïve patients. BJU Int 2018; 121: 53–60.PubMedCrossRef Borkowetz A, Hadaschik B, Platzek I, Toma M, Torsev G, Renner T, Herout R, Baunacke M, Laniado M, Baretton G, Radtke JP, Kesch C, Hohenfellner M, Froehner M, Schlemmer HP, Wirth M, Zastrow S. Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naïve patients. BJU Int 2018; 121: 53–60.PubMedCrossRef
42.
go back to reference Borkowetz A, Renner T, Platzek I, Toma M, Herout R, Baunacke M, Groeben C, Huber J, Laniado M, Baretton G, Froehner M, Zastrow S, Wirth MP. Evaluation of Transperineal Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy Compared to Transrectal Systematic Biopsy in the Prediction of Tumour Aggressiveness in Patients with Previously Negative Biopsy. Urol Int 2019; 102: 20–26.PubMedCrossRef Borkowetz A, Renner T, Platzek I, Toma M, Herout R, Baunacke M, Groeben C, Huber J, Laniado M, Baretton G, Froehner M, Zastrow S, Wirth MP. Evaluation of Transperineal Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy Compared to Transrectal Systematic Biopsy in the Prediction of Tumour Aggressiveness in Patients with Previously Negative Biopsy. Urol Int 2019; 102: 20–26.PubMedCrossRef
43.
go back to reference Borkowetz A, Renner T, Platzek I, Toma M, Herout R, Baunacke M, Groeben C, Huber J, Laniado M, Baretton GB, Froehner M, Zastrow S, Wirth MP. Evaluation of Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy in Patients with Low-Risk Prostate Cancer Under Active Surveillance Undergoing Surveillance Biopsy. Urol Int 2018; 100: 155–163.PubMedCrossRef Borkowetz A, Renner T, Platzek I, Toma M, Herout R, Baunacke M, Groeben C, Huber J, Laniado M, Baretton GB, Froehner M, Zastrow S, Wirth MP. Evaluation of Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy in Patients with Low-Risk Prostate Cancer Under Active Surveillance Undergoing Surveillance Biopsy. Urol Int 2018; 100: 155–163.PubMedCrossRef
44.
go back to reference Hansen NL, Barrett T, Kesch C, Pepdjonovic L, Bonekamp D, O’Sullivan R, Distler F, Warren A, Samel C, Hadaschik B, Grummet J, Kastner C. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer. BJU Int 2018; 122: 40–49.PubMedCrossRef Hansen NL, Barrett T, Kesch C, Pepdjonovic L, Bonekamp D, O’Sullivan R, Distler F, Warren A, Samel C, Hadaschik B, Grummet J, Kastner C. Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer. BJU Int 2018; 122: 40–49.PubMedCrossRef
45.
go back to reference Hansen NL, Kesch C, Barrett T, Koo B, Radtke JP, Bonekamp D, Schlemmer HP, Warren AY, Wieczorek K, Hohenfellner M, Kastner C, Hadaschik B. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU Int. 2017; 120: 631–638.PubMedCrossRef Hansen NL, Kesch C, Barrett T, Koo B, Radtke JP, Bonekamp D, Schlemmer HP, Warren AY, Wieczorek K, Hohenfellner M, Kastner C, Hadaschik B. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU Int. 2017; 120: 631–638.PubMedCrossRef
46.
go back to reference Kaneko M, Medina LG, Lenon MSL, Hemal S, Sayegh AS, Jadvar DS, Ramacciotti LS, Paralkar D, Cacciamani GE, Lebastchi AH, Salhia B, Aron M, Hopstone M, Duddalwar V, Palmer SL, Gill IS, Abreu AL. Transperineal vs transrectal magnetic resonance and ultrasound image fusion prostate biopsy: a pair-matched comparison. Sci Rep. 2023;13: 13457.PubMedPubMedCentralCrossRef Kaneko M, Medina LG, Lenon MSL, Hemal S, Sayegh AS, Jadvar DS, Ramacciotti LS, Paralkar D, Cacciamani GE, Lebastchi AH, Salhia B, Aron M, Hopstone M, Duddalwar V, Palmer SL, Gill IS, Abreu AL. Transperineal vs transrectal magnetic resonance and ultrasound image fusion prostate biopsy: a pair-matched comparison. Sci Rep. 2023;13: 13457.PubMedPubMedCentralCrossRef
47.
go back to reference Rai BP, Mayerhofer C, Somani BK, Kallidonis P, Nagele U, Tokas T. Magnetic Resonance Imaging/Ultrasound Fusion-guided Transperineal Versus Magnetic Resonance Imaging/Ultrasound Fusion-guided Transrectal Prostate Biopsy-A Systematic Review. Eur Urol Oncol 2021; 4: 904–913.PubMedCrossRef Rai BP, Mayerhofer C, Somani BK, Kallidonis P, Nagele U, Tokas T. Magnetic Resonance Imaging/Ultrasound Fusion-guided Transperineal Versus Magnetic Resonance Imaging/Ultrasound Fusion-guided Transrectal Prostate Biopsy-A Systematic Review. Eur Urol Oncol 2021; 4: 904–913.PubMedCrossRef
48.
go back to reference Pepe P, Garufi A, Priolo G, et al. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer. Clin Genitourin Cancer 2017;15:e33-6.CrossRef Pepe P, Garufi A, Priolo G, et al. Transperineal Versus Transrectal MRI/TRUS Fusion Targeted Biopsy: Detection Rate of Clinically Significant Prostate Cancer. Clin Genitourin Cancer 2017;15:e33-6.CrossRef
50.
go back to reference Ber Y, Segal N, Tamir S, Benjaminov O, Yakimov M, Sela S, Halstauch D, Baniel J, Kedar D, Margel D. A noninferiority within-person study comparing the accuracy of transperineal to transrectal MRI-US fusion biopsy for prostate-cancer detection. Prostate Cancer Prostatic Dis 2020; 23: 449–456.PubMedPubMedCentralCrossRef Ber Y, Segal N, Tamir S, Benjaminov O, Yakimov M, Sela S, Halstauch D, Baniel J, Kedar D, Margel D. A noninferiority within-person study comparing the accuracy of transperineal to transrectal MRI-US fusion biopsy for prostate-cancer detection. Prostate Cancer Prostatic Dis 2020; 23: 449–456.PubMedPubMedCentralCrossRef
51.
go back to reference Uleri A, Baboudjian M, Tedde A, Gallioli A, Long-Depaquit T, Palou J, Basile G, Gaya JM, Sanguedolce F, Lughezzani G, Rajwa P, Pradere B, Roupret M, Briganti A, Ploussard G, Breda A. Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy in Clinically Significant Prostate Cancer Detection Rate? A Systematic Review and Meta-analysis. Eur Urol Oncol 2023;6: 621–628.PubMedCrossRef Uleri A, Baboudjian M, Tedde A, Gallioli A, Long-Depaquit T, Palou J, Basile G, Gaya JM, Sanguedolce F, Lughezzani G, Rajwa P, Pradere B, Roupret M, Briganti A, Ploussard G, Breda A. Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy in Clinically Significant Prostate Cancer Detection Rate? A Systematic Review and Meta-analysis. Eur Urol Oncol 2023;6: 621–628.PubMedCrossRef
52.
go back to reference Touzani A, Fiard G, Barret E, Renard-Penna R, Salin A, Pradère B, Rozet F, Beauval JB, Malavaud B, Giannarini G, Colin P, Rouprêt M, Ploussard G. Clinical Trial Protocol for PERFECT: A Randomised Controlled Trial Comparing the Efficiency and Tolerance of Transperineal Fusion Versus Transrectal Imaging-targeted Prostate Biopsies (CCAFU-PR1 Study). Eur Urol Open Sci 2022; 45: 76–80.PubMedPubMedCentralCrossRef Touzani A, Fiard G, Barret E, Renard-Penna R, Salin A, Pradère B, Rozet F, Beauval JB, Malavaud B, Giannarini G, Colin P, Rouprêt M, Ploussard G. Clinical Trial Protocol for PERFECT: A Randomised Controlled Trial Comparing the Efficiency and Tolerance of Transperineal Fusion Versus Transrectal Imaging-targeted Prostate Biopsies (CCAFU-PR1 Study). Eur Urol Open Sci 2022; 45: 76–80.PubMedPubMedCentralCrossRef
53.
go back to reference Penzkofer T, Tuncali K, Fedorov A, Song SE, Tokuda J, Fennessy FM, Vangel MG, Kibel AS, Mulkern RV, Wells WM, Hata N, Tempany CM. Transperineal inbore 3-T MR imaging-guided prostate biopsy: a prospective clinical observational study. Radiology 2015; 274: 170–180.PubMedCrossRef Penzkofer T, Tuncali K, Fedorov A, Song SE, Tokuda J, Fennessy FM, Vangel MG, Kibel AS, Mulkern RV, Wells WM, Hata N, Tempany CM. Transperineal inbore 3-T MR imaging-guided prostate biopsy: a prospective clinical observational study. Radiology 2015; 274: 170–180.PubMedCrossRef
54.
go back to reference Velez E, Fedorov A, Tuncali K, Olubiyi O, Allard CB, Kibel AS, Tempany CM. Pathologic correlation of transperineal in-bore 3-Tesla magnetic resonance imaging-guided prostate biopsy samples with radical prostatectomy specimen. Abdom Radiol 2017; 42: 2154–2159CrossRef Velez E, Fedorov A, Tuncali K, Olubiyi O, Allard CB, Kibel AS, Tempany CM. Pathologic correlation of transperineal in-bore 3-Tesla magnetic resonance imaging-guided prostate biopsy samples with radical prostatectomy specimen. Abdom Radiol 2017; 42: 2154–2159CrossRef
55.
go back to reference Egbers N, Schwenke C, Maxeiner A, Teichgräber U, Franiel T. MRI-guided core needle biopsy of the prostate: acceptance and side effects. Diagn Interv Radiol. 2015; 21: 215–21.PubMedPubMedCentralCrossRef Egbers N, Schwenke C, Maxeiner A, Teichgräber U, Franiel T. MRI-guided core needle biopsy of the prostate: acceptance and side effects. Diagn Interv Radiol. 2015; 21: 215–21.PubMedPubMedCentralCrossRef
56.
go back to reference Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, Vergunst H, Sedelaar JP, Fütterer JJ, Barentsz JO. Three-tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: Detection of clinically significant prostate cancers. European Urology 2012; 62: 902–9.PubMedCrossRef Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, Vergunst H, Sedelaar JP, Fütterer JJ, Barentsz JO. Three-tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: Detection of clinically significant prostate cancers. European Urology 2012; 62: 902–9.PubMedCrossRef
57.
go back to reference Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology. 2002; 60: 826–30.PubMedCrossRef Raaijmakers R, Kirkels WJ, Roobol MJ, Wildhagen MF, Schrder FH. Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program. Urology. 2002; 60: 826–30.PubMedCrossRef
58.
go back to reference Chiang IN, Chang SJ, Pu YS, Huang KH, Yu HJ, Huang CY. Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: a retrospective study of 1875 cases in Taiwan. J Formos Med Assoc 2007; 106: 929–34.PubMedCrossRef Chiang IN, Chang SJ, Pu YS, Huang KH, Yu HJ, Huang CY. Major complications and associated risk factors of transrectal ultrasound guided prostate needle biopsy: a retrospective study of 1875 cases in Taiwan. J Formos Med Assoc 2007; 106: 929–34.PubMedCrossRef
59.
go back to reference Symons JL, Huo A, Yuen CL, Haynes AM, Matthews J, Sutherland RL, Brenner P, Stricker PD. Outcomes of transperineal template-guided prostate biopsy in 409 patients. BJU Int 2013; 112: 585–93.PubMedCrossRef Symons JL, Huo A, Yuen CL, Haynes AM, Matthews J, Sutherland RL, Brenner P, Stricker PD. Outcomes of transperineal template-guided prostate biopsy in 409 patients. BJU Int 2013; 112: 585–93.PubMedCrossRef
60.
go back to reference Buskirk SJ, Pinkstaff DM, Petrou SP, Wehle MJ, Broderick GA, Young PR, Weigand SD, O’Brien PC, Igel TC. Acute urinary retention after transperineal template-guided prostate biopsy. Int J Radiat Oncol Biol Phys 2004; 59: 1360–6.PubMedCrossRef Buskirk SJ, Pinkstaff DM, Petrou SP, Wehle MJ, Broderick GA, Young PR, Weigand SD, O’Brien PC, Igel TC. Acute urinary retention after transperineal template-guided prostate biopsy. Int J Radiat Oncol Biol Phys 2004; 59: 1360–6.PubMedCrossRef
61.
go back to reference Wegelin O, Exterkate L, van der Leest M, Kelder JC, Bosch JLHR, Barentsz JO, Somford DM, van Melick HHE. Complications and Adverse Events of Three Magnetic Resonance Imaging-based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial. Eur Urol Oncol. 2019;2(6):617–624. doi: 10.1016/j.euo.2019.08.007. Epub 2019 Sep 11. PMID: 31519516. Wegelin O, Exterkate L, van der Leest M, Kelder JC, Bosch JLHR, Barentsz JO, Somford DM, van Melick HHE. Complications and Adverse Events of Three Magnetic Resonance Imaging-based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial. Eur Urol Oncol. 2019;2(6):617–624. doi: 10.1016/j.euo.2019.08.007. Epub 2019 Sep 11. PMID: 31519516.
62.
go back to reference Eklund M, Jäderling F, Discacciati A, Bergman M, Annerstedt M, Aly M, Glaessgen A, Carlsson S, Grönberg H, Nordström T; STHLM3 consortium. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. N Engl J Med. 2021; 385: 908–920.PubMedCrossRef Eklund M, Jäderling F, Discacciati A, Bergman M, Annerstedt M, Aly M, Glaessgen A, Carlsson S, Grönberg H, Nordström T; STHLM3 consortium. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. N Engl J Med. 2021; 385: 908–920.PubMedCrossRef
63.
go back to reference Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: Implications for focal therapy. Prostate Cancer and Prostatic Diseases 2011; 14: 46–52.PubMedCrossRef Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: Implications for focal therapy. Prostate Cancer and Prostatic Diseases 2011; 14: 46–52.PubMedCrossRef
64.
go back to reference Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall’Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Maroni P, Ponsky L, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Smaldone MC, Sonn G, Tyson MD, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi RA, Freedman-Cass DA. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. J Natl Compr Canc Netw 2023;21: 236–246.Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Konety BR, Miner M, Moses K, Nissenberg MG, Pinto PA, Salami SS, Souter L, Thompson IM, Lin DW. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol 2023; 210: 54–63. Moses KA, Sprenkle PC, Bahler C, Box G, Carlsson SV, Catalona WJ, Dahl DM, Dall’Era M, Davis JW, Drake BF, Epstein JI, Etzioni RB, Farrington TA, Garraway IP, Jarrard D, Kauffman E, Kaye D, Kibel AS, LaGrange CA, Maroni P, Ponsky L, Reys B, Salami SS, Sanchez A, Seibert TM, Shaneyfelt TM, Smaldone MC, Sonn G, Tyson MD, Vapiwala N, Wake R, Washington S, Yu A, Yuh B, Berardi RA, Freedman-Cass DA. NCCN Guidelines® Insights: Prostate Cancer Early Detection, Version 1.2023. J Natl Compr Canc Netw 2023;21: 236–246.Wei JT, Barocas D, Carlsson S, Coakley F, Eggener S, Etzioni R, Fine SW, Han M, Kim SK, Kirkby E, Konety BR, Miner M, Moses K, Nissenberg MG, Pinto PA, Salami SS, Souter L, Thompson IM, Lin DW. Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy. J Urol 2023; 210: 54–63.
65.
go back to reference Bjurlin MA, Carroll PR, Eggener S, Fulgham PF, Margolis DJ, Pinto PA, Rosenkrantz AB, Rubenstein JN, Rukstalis DB, Taneja SS, Turkbey B. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. J Urol 2020; 203: 706–712.PubMedCrossRef Bjurlin MA, Carroll PR, Eggener S, Fulgham PF, Margolis DJ, Pinto PA, Rosenkrantz AB, Rubenstein JN, Rukstalis DB, Taneja SS, Turkbey B. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. J Urol 2020; 203: 706–712.PubMedCrossRef
66.
go back to reference Expert Panel on Urologic Imaging:; Coakley FV, Oto A, Alexander LF, Allen BC, Davis BJ, Froemming AT, Fulgham PF, Hosseinzadeh K, Porter C, Sahni VA, Schuster DM, Showalter TN, Venkatesan AM, Verma S, Wang CL, Remer EM, Eberhardt SC. ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. J Am Coll Radiol 2017; 14:S245-S257. Expert Panel on Urologic Imaging:; Coakley FV, Oto A, Alexander LF, Allen BC, Davis BJ, Froemming AT, Fulgham PF, Hosseinzadeh K, Porter C, Sahni VA, Schuster DM, Showalter TN, Venkatesan AM, Verma S, Wang CL, Remer EM, Eberhardt SC. ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. J Am Coll Radiol 2017; 14:S245-S257.
Metadata
Title
Targeted biopsy of the prostate
Authors
David W. Schroeder
Bryan R. Foster
Daniel J. Young
Fergus V. Coakley
Publication date
08-07-2024
Publisher
Springer US
Published in
Abdominal Radiology
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-024-04452-z
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare